Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 2/20 | 0.40 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849479 | 1.00 | POLB (0.43) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL2843566 | 1.00 | POLB (0.43) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL29412367 | 0.89 | PDK1 (0.35) | POLBDPP4DPP8HDAC8HDAC6 | |
| SCHEMBL27319486 | 0.89 | PDK1 (0.35) | POLBDPP4DPP8HDAC8HDAC6 | |
| SCHEMBL4023639 | 0.85 | POLB (0.46) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL30639674 | 0.84 | POLB (0.42) | POLBL3MBTL1HDAC8HDAC6HDAC1 | |
| SCHEMBL11967766 | 0.84 | POLB (0.44) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL12409378 | 0.84 | POLB (0.44) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL3178302 | 0.84 | POLB (0.44) | POLBL3MBTL1DPP4DPP8HDAC8 | |
| SCHEMBL3182268 | 0.84 | POLB (0.44) | POLBL3MBTL1DPP4DPP8HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| US-20220298107-A1 | SUBSTITUTED UREA DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114286813-A | Substituted urea dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-04-05 | — | — | CN | disclosed |
| US-9518056-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | POLB 1346/4885L3MBTL1 3610/4885DPP4 1865/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | POLB 800/4885L3MBTL1 3645/4885DPP4 2022/4885 |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | POLB 3099/4885L3MBTL1 4663/4885DPP4 38/4885 |
| US-20220298107-A1 | SUBSTITUTED UREA DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DPYD, UGDH | POLB 734/4885L3MBTL1 1906/4885DPP4 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.